secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-09-10T10:14:01+00:00
Accession:  0001493152-26-042052
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine to present at H.C. Wainwright 28th Annual Global Investment Conference
-------------------------------------------------------------------------------

- Management to present and hold one-on-one meetings at H.C. Wainwright conference in New York, Sept 14-16, 2026.
- Presentation scheduled for Wednesday, September 16, 2026 at 10:00 a.m. ET; webcast archived for 90 days.
- Pipeline includes LPCN 1154 (postpartum depression), LPCN 2201 (MDD), LPCN 2101 (epilepsy), LPCN 2203 (essential tremor), LPCN 2401 (obesity), LPCN 1148 (liver cirrhosis), LPCN 1107 (preterm birth).
- TLANDO (oral testosterone undecanoate) remains FDA-approved for hypogonadism in adult males.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226042052/0001493152-26-042052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226042052/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-042052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer